Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Goodman

Showing results (901-910 of 1,119) with videos related to

Pageof 112
Sort By:
Circulation|April 20, 2011
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue, Deepak L Bhatt, Stephen D Wiviott, et al.
Journal of Cardiology|December 3, 2021
Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registryJuan J Russo, Andrew T Yan, Stuart J Pocock, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 25, 2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialPatrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, et al.
Current Oncology (Toronto, Ont.)|May 24, 2024
New Anticancer Drugs: Reliably Assessing "Value" While Addressing High PricesDavid J Stewart, John-Peter Bradford, Sandeep Sehdev, et al.
The Lancet. Diabetes & Endocrinology|April 4, 2022
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trialPetr Ostadal, Philippe Gabriel Steg, Yann Poulouin, et al.
Journal of the American Society of Nephrology : JASN|December 16, 2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE TrialSharon M Moe, Safa Abdalla, Glenn M Chertow, et al.
American Heart Journal|February 16, 2018
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trialMatthew W Sherwood, Renato D Lopes, Jie Lena Sun, et al.
Heart (British Cardiac Society)|June 26, 2015
Characterising and predicting bleeding in high-risk patients with an acute coronary syndromeRazi Khan, Renato D Lopes, Megan L Neely, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
The impact of postrandomization crossover of therapy in acute coronary syndromes careKenneth W Mahaffey, Karen S Pieper, Yuliya Lokhnygina, et al.
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Pageof 112

Showing results (901-910 of 1,119) with videos related to

Sort By:
Pageof 112
Circulation|April 20, 2011
Safety and tolerability of atopaxar in the treatment of patients with acute coronary syndromes: the lessons from antagonizing the cellular effects of Thrombin–Acute Coronary Syndromes TrialMichelle L O'Donoghue, Deepak L Bhatt, Stephen D Wiviott, et al.
Journal of Cardiology|December 3, 2021
Determinants of long-term dual antiplatelet therapy use in post myocardial infarction patients: Insights from the TIGRIS registryJuan J Russo, Andrew T Yan, Stuart J Pocock, et al.
Clinical Journal of the American Society of Nephrology : CJASN|February 25, 2015
The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialPatrick S Parfrey, Tilman B Drüeke, Geoffrey A Block, et al.
Current Oncology (Toronto, Ont.)|May 24, 2024
New Anticancer Drugs: Reliably Assessing "Value" While Addressing High PricesDavid J Stewart, John-Peter Bradford, Sandeep Sehdev, et al.
The Lancet. Diabetes & Endocrinology|April 4, 2022
Metabolic risk factors and effect of alirocumab on cardiovascular events after acute coronary syndrome: a post-hoc analysis of the ODYSSEY OUTCOMES randomised controlled trialPetr Ostadal, Philippe Gabriel Steg, Yann Poulouin, et al.
Journal of the American Society of Nephrology : JASN|December 16, 2014
Effects of Cinacalcet on Fracture Events in Patients Receiving Hemodialysis: The EVOLVE TrialSharon M Moe, Safa Abdalla, Glenn M Chertow, et al.
American Heart Journal|February 16, 2018
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trialMatthew W Sherwood, Renato D Lopes, Jie Lena Sun, et al.
Heart (British Cardiac Society)|June 26, 2015
Characterising and predicting bleeding in high-risk patients with an acute coronary syndromeRazi Khan, Renato D Lopes, Megan L Neely, et al.
Circulation. Cardiovascular Quality and Outcomes|February 10, 2011
The impact of postrandomization crossover of therapy in acute coronary syndromes careKenneth W Mahaffey, Karen S Pieper, Yuliya Lokhnygina, et al.
Circulation|June 11, 2015
Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) TrialSharon M Moe, Glenn M Chertow, Patrick S Parfrey, et al.
Pageof 112